Four leading companies CTMC, Iovance Therapeutics, KSQ, and TILT Biotherapeutics prognosticate coming successes of new technology approaches to better tumor-infiltrating lymphocyte activities.

Researchers presented a first study on biological pathways perturbed in association with CRCI, anxiety, and co-occurring CRCI.